GLI1 and breast carcinoma: In breast cancer, pathway activation of CSCs using Shh and Gli1 or Gli2 expression or inhibition with cyclopamine or siRNA mediated against Gli1 or Gli2 alters the expression of Bmi1, which is a central regulator of self-renewal in normal stem cells and tumorigenic potential in vitro and in vivo31.